Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry

The effectiveness and safety of biological disease-modifying antirheumatic drugs (bDMARDs) by age group (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis research & therapy 2020-06, Vol.22 (1), p.136-12, Article 136
Hauptverfasser:	Kawabe, Akio, Nakano, Kazuhisa, Kubo, Satoshi, Asakawa, Takeshi, Tanaka, Yoshiya
Format:	Artikel
Sprache:	eng
Schlagworte:	Abatacept - therapeutic use Activities of daily living Adalimumab Age groups Aged Antirheumatic Agents Arthritis Arthritis, Rheumatoid - drug therapy Bias Biological disease-modifying antirheumatic drugs Certolizumab pegol Clinical medicine Data analysis Drug dosages Drug therapy Generalized propensity score Golimumab Health aspects Humans Inverse probability of treatment weighting Methods Monoclonal antibodies Older people Patients Performance evaluation Population Registries Retention Retention rate Rheumatoid arthritis Rheumatoid factor Rheumatology Society Treatment Outcome Tumor necrosis factor Tumor Necrosis Factor-alpha
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The effectiveness and safety of biological disease-modifying antirheumatic drugs (bDMARDs) by age group (
ISSN:	1478-6362 1478-6354 1478-6362
DOI:	10.1186/s13075-020-02233-9